J Rosenstock, AJ Ahmann, G Colon, J Scism-Bacon … - Diabetes Care, 2008 - Am Diabetes Assoc RESULTS—Baseline A1C was similar (PPT 8.8%; BBT 8.9%; P = 0.598). At week 24, A1C was
lower with BBT (6.78 vs. 6.95%, P = 0.021). A1C was reduced significantly from baseline for both
therapies (P < 0.0001). The difference in A1C change from baseline to the end point (BBT ... Cited by 29 - Related articles - BL Direct - All 5 versions
RJMU Ligthelm, HLOM Lynggaard, CDC Fox … - Experimental and …, 2006 - 万方数据资源系统 AIMS: To show that a thrice daily meal-time biphasic insulin aspart (BIAsp) treatment regimen
is as efficacious as a 4 times daily basal-bolus regimen with human isophane insulin (NPH) and
insulin aspart (IAsp). METHODS: A multinational, randomised, open-label parallel-group ... Cited by 22 - Related articles - BL Direct - All 4 versions
C Kazda, H Hülstrunk, K Helsberg, F Langer, T … - Journal of diabetes and its …, 2006 - Elsevier This was an open-label, randomized, parallel, three-arm multicenter trial in patients with type
2 diabetes starting insulin treatment. Patients (n=159) were randomly assigned to 24-week treatment
with 3× daily insulin lispro, 3× daily lispro mid mixture (MidMix; 50% lispro, 50% ... Cited by 26 - Related articles - All 10 versions
R Qayyum, S Bolen, N Maruthur, L Feldman, … - Annals of Internal …, 2008 - Am Coll Physicians Background: Evidence comparing premixed insulin analogues (a mixture of rapid-acting and
intermediate-acting insulin analogues) with other antidiabetic agents is urgently required to guide
appropriate therapy. ... Purpose: To summarize the English-language literature on the ... Cited by 20 - Related articles - All 8 versions
DC Robbins, PJ Beisswenger, A Ceriello, RB Goldberg … - Clinical therapeutics, 2007 - Elsevier Background: In people without diabetes, 50% of daily insulin secretion is basal and the remainder
is postprandial. Hence, it would be expected that insulin replacement therapy in a 50/50 ratio
with each meal would mimic physiologic insulin secretion better than treatment with once- ... Cited by 9 - Related articles - All 3 versions
SJ Jacober, JL Scism-Bacon, AJ … - Diabetes Obesity and …, 2006 - interscience.wiley.com Aim: In patients with type 2 diabetes, insulin therapy is commonly initiated with either a single
dose of basal insulin or twice-daily premixed (basal plus prandial) insulin despite no widely accepted
recommendation. We compared the glycaemic control, as measured by a change in ... Cited by 14 - Related articles - BL Direct - All 4 versions
- ►pipex.com [PDF] RR Holman, KI Thorne, AJ Farmer, MJ Davies … - New England Journal …, 2007 - content.nejm.org From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism
(RRH, KIT, AJF, JFK, SP, JCL) and the Department of Primary Health Care (AJF), University of
Oxford, Oxford; and the Department of Cardiovas- cular Sciences, University of Leicester, ... Cited by 137 - Related articles - BL Direct - All 12 versions
- ►annals.org [PDF] K Esposito, M Ciotola, MI Maiorino, R … - Annals of internal …, 2008 - Am Coll Physicians Background: Injection of long-acting insulin at bedtime is a com- mon therapeutic approach for
patients with type 2 diabetes that is poorly controlled with oral regimens. Neutral protamine lispro
(NPL) insulin has demonstrated better glycemic control and similar inci- dence of ... Cited by 7 - Related articles - All 7 versions
K Horvath, K Jeitler, A Berghold, SH Ebrahim, … - Cochrane database of …, 2007 - ncbi.nlm.nih.gov BACKGROUND: Despite indications from epidemiological trials that higher blood glucose concentrations
are associated with a higher risk for developing micro- and macrovascular complications, evidence
for a beneficial effect of antihyperglycaemic therapy in patients with type 2 diabetes ... Cited by 73 - Related articles - BL Direct
- ►nih.gov J Rosenstock, M Davies, PD Home, J Larsen, C … - Diabetologia, 2008 - Springer Abstract Aims/hypothesis This 52-week multinational, randomised, open-label,
parallel-group, non-inferiority trial compared clinical outcomes following supplementation of
oral glu- cose-lowering drugs with basal insulin analogues detemir and glargine in type 2 ... Cited by 75 - Related articles - BL Direct - All 9 versions
